Chelsea Therapeutics International is a biopharmaceutical company engaged in acquiring and developing innovative products to treat a variety of human diseases, including disorders of the central nervous system. The company is presently pursuing FDA approval in the United States for Northera (droxidopa), which is a novel, late-stage, orally active therapeutic agent for treating symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information, visit the company’s Web site at www.chelseatherapeutics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: